BioSpace News Archive

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company focused on delivering genomic technologies for the advancement of science and medicine, today highlighted recent corporate achievements and reported financial results for the third quarter of 2021.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the quarter ended September 30, 2021.

Timber Pharmaceuticals, Inc. announced that the underwriter of its previously announced underwritten public offering which closed on November 5, 2021 has exercised in full the remainder of its option to purchase an additional 3,515,625 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced recent highlights and reported third quarter 2021 financial results.

Avalo Therapeutics, Inc., a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases announced business updates and third quarter 2021 financial results.

Adagene Inc., a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, announced that members of the company’s management will participate virtually in the following investor and industry conferences during November 2021:

Capricor Therapeutics, a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, reported its financial results for the third quarter ended September 30, 2021, and provided an overview of its recent operational highlights.

Nurix Therapeutics, Inc., a biopharmaceutical company developing targeted protein modulation drugs, announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in fireside chats at the following conferences in November:.

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended September 30, 2021 and provided a corporate update.

ImmuCell Corporation, a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the third quarter and the nine-month period ended September 30, 2021 after the market closes on Monday, November 15, 2021.